Medicxi Ventures Management (Jersey) Ltd
In its 13F for Q2 2025 (holdings as of June 30, 2025, filed July 8, 2025), Medicxi Ventures Management (Jersey) Ltd reported 5 stock positions worth $427.3 million. Its top holding was Centessa Pharmaceuticals (CNTA) at 61.4% of the portfolio, followed by Phathom Pharmaceuticals (PHAT, 16.8%) and Newamsterdam Pharma (NAMS, 12.2%). Compared with Q1 2025, it opened 1 new position and sold out of 1. The biggest buy was a new position in Rapt Therapeutics (RAPT) and the biggest sale an exit from Rapt Therapeutics.
- Most Recent 13F
- Q2 2026
- Location
- ST. HELIER, Y9
- CIK
- 0001715579
- Portfolio Value
- $427.3M (Q2 2025)
- SEC Filing
- 0000950123-25-006205 ↗ filed Jul 8, 2025
Holdings Value
Holdings 5 stocks · $427.3M
| CNTA Centessa Pharmaceuticals Ltd. | 61.40% | 19,963,157 | $262.3M | No change |
| PHAT Phathom Pharmaceuticals Inc. | 16.75% | 7,464,572 | $71.6M | No change |
| NAMS Newamsterdam Pharma Co. NV | 12.16% | 2,869,565 | $52.0M | No change |
| RAPT Rapt Therapeutics Inc. | 5.23% | 2,794,000 | $22.4M | New |
| AURA Aura Biosciences Inc. | 4.45% | 3,039,892 | $19.0M | No change |
Portfolio Sells Q1 2025 → Q2 2025
| RAPT THERAPEUTICS INC | Sold out | 0.00% | −6.23 |
Portfolio Buys Q1 2025 → Q2 2025
| RAPT Rapt Therapeutics Inc. | New | 5.23% | +5.23 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 3 | $177.4M | PHAT, NAMS, AURA |
| Q1 2026 | 4 | $981.8M | CNTA, NAMS, PHAT, AURA |
| Q4 2025 | 5 | $835.0M | CNTA, PHAT, NAMS, RAPT THERAPEUTICS INC, AURA |
| Q3 2025 | 5 | $744.4M | CNTA, PHAT, NAMS, RAPT THERAPEUTICS INC, AURA |
| Q2 2025 | 5 | $427.3M | CNTA, PHAT, NAMS, RAPT, AURA |
| Q1 2025 | 5 | $437.7M | CNTA, NAMS, PHAT, RAPT THERAPEUTICS INC, AURA |
| Q4 2024 | 5 | $529.0M | CNTA, NAMS, PHAT, RAPT THERAPEUTICS INC, AURA |
| Q3 2024 | 4 | $528.9M | CNTA, PHAT, NAMS, AURA |
| Q2 2024 | 4 | $335.3M | CNTA, PHAT, NAMS, AURA |
| Q1 2024 | 5 | $449.2M | CNTA, PHAT, NAMS, MRUS, AURA |